Nasdaq btai.
586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ...
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning ...Investigation Alert BAX, DHR, BTAI, and IBRX: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below GlobeNewswire Sep 26, 2023 4:27pm Trading InformationBioXcel Therapeutics Inc (NASDAQ:BTAI) BioXcel Therapeutics Inc. 4.13. Delayed Data. As of Nov 17. -0.12 / -2.82%. Today’s Change. 2.23.Aug 14, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...
NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...BTAI BTAI AFTER HOURS QUOTE BTAI LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...
Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact: Joshua M. Lifshitz, Esq. Lifshitz Law PLLC. Phone: 516-493-9780. Facsimile: 516-280-7376 ...BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ...
Find the latest Insider Activity data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.Real time BioXcel Therapeutics (BTAI) stock price quote, stock graph, news & analysis.BioXcel Therapeutics, Inc. Common Stock (BTAI) Nasdaq Listed. DATA AS OF Nov 12, 2021. 0. Add to Watchlist.NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...BioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST. 3.9999 +0.10 (+2.56%) After hours:...
BRANFORD, Conn., June 07, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial ...
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...
On track to submit complete NDA in Q1 2021. NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...OnkosXcel is a subsidiary of BioXcel Therapeutics, Inc. (Nasdaq: BTAI). This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, ...The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023. The analyst firm set a price target for 11.00 expecting BTAI ...BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program of BXCL501 for acute treatment of agitation associated The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023.
2017. 183. Vimal Mehta. https://www.bioxceltherapeutics.com. BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dropped 21.2% to settle at $27.21 after Goldman Sachs downgraded the stock from Buy to Sell and lowered its price target from $55 to $24.BioXcel Therapeutics (NASDAQ:BTAI) announces that the FDA has accepted for filing the New Drug Application (NDA) for BXCL501, an investigational, orally dissolving thin film formulation of ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dropped 21.2% to settle at $27.21 after Goldman Sachs downgraded the stock from Buy to Sell and lowered its price target from $55 to $24.
BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...BioXcel Therapeutics will host a conference call and webcast at 8:30 a.m. ET on March 9 to discuss its fourth quarter and full-year 2022 financial results and provide an update on recent ...
Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 586.04% Upside. As of ...Nasdaq: BTAI PRICE 3.93 CHANGE 0 (0%)BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today ...A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM Mar 15, 2021 · NEW HAVEN, Conn., March 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ... Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.
BioXcel Therapeutics, Inc. (BTAI). NASDAQ: BTAI · IEX Real-Time Price · USD.
Nov 8, 2023 · AI. BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
22 Aug 2023 ... (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class ...Nov 14, 2023 · BioXcel Therapeutics (NASDAQ:BTAI) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. BioXcel ... Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023.BioXcel Therapeutics Inc. Follow. Share. $3.93. After Hours: $3.90. (0.76%) -0.030. Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer. search Compare to.Nov 25, 2023 · Isaac Mitchell. November 25, 2023. Technologies. BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.78. At the close of trading, the stock’s price was $4.00, to imply an increase of 4.44% or $0.17 in intraday trading. The BTAI share’s 52-week high ... BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced proof-of-concept data from its Phase 1b study of ...NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”), a commercial-stage biopharmaceutical company ...Real time BioXcel Therapeutics (BTAI) stock price quote, stock graph, news & analysis.Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...
BTAI DEADLINE: ROSEN, ... (NASDAQ: BTAI) between... BTAI: 3.93 (+2.61%) BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options PR Newswire - Sat Sep 2, 6:00AM CDT ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...Instagram:https://instagram. expensive quarterstmf ex dividend datereit medical propertiesbest penny stocks under 1 cent BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ... 2023 corvette z06 70th anniversary priceoptions profit calc BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ... banks stock Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain ...Following a 60% decline over last year, recent gains may please BioXcel Therapeutics, Inc. (NASDAQ:BTAI) institutional owners Read full article [email protected] (Simply Wall St)